Urea Breath Test Market By Product Type (¹³C Urea Breath Test Kits, Breath Analyzers and Detection Systems); By Test Type (Laboratory-Based Urea Breath Testing, Point-of-Care Testing (POCT)); By Application / End User (Hospitals, Diagnostic Centers & Standalone Laboratories, Specialized Gastroenterology Clinics, Physical Examination and Wellness Centers); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Urea Breath Testing Moves H. pylori Diagnosis Closer to the Patient – (Updated On: 28th-Sep-2026)

The Global Urea Breath Test Market was valued at USD 405 million in 2025 and is projected to reach USD 606 million by 2032, expanding at a CAGR of 5.85% during 2026–2032, according to Strategic Market Research.

 

The Urea Breath Test Market represents the global demand for diagnostic solutions used to detect active Helicobacter pylori (H. pylori) infection through breath analysis. The market includes ¹³C-urea and ¹4C-urea test kits, automated breath analyzers, isotope detection systems, and integrated laboratory or point-of-care testing platforms.

 

A global systematic analysis covering 111 countries and 6.27 million individuals reported an overall infection prevalence of approximately 43.9% among adults and 35.1% among children and adolescents during 2015–2022. The infection burden remains particularly significant across Asia-Pacific, Latin America, and parts of Africa, where prevalence in several countries exceeds 50%

 

The competitive landscape is shaped by companies developing automated testing platforms, isotope-based diagnostic technologies, and integrated gastrointestinal testing solutions. Meridian Bioscience, Inc. has expanded automated breath testing capabilities through its BreathID platform, which enables real-time analysis and digital reporting. SSI Diagnostica Group provides PyloPlus® ¹³C-urea breath testing solutions, while Kibion AB focuses on global carbon-13 breath testing technologies. Diagnostic service providers such as Quest Diagnostics and Labcorp contribute through centralized testing services, while regional manufacturers support analyzer supply and cost-efficient testing expansion.

 

Overall, the Urea Breath Test Market is transitioning from a laboratory-focused diagnostic segment into a broader non-invasive gastrointestinal testing ecosystem. Rising global H. pylori prevalence, increasing demand for accurate treatment confirmation, healthcare cost optimization, and advances in portable breath analytics are expected to sustain market expansion through 2032.

 

¹³C Kits Anchor Revenue While Decentralized Testing Gains Pace

By Product Type

Leading Segment: ¹³C Urea Breath Test Kits

¹³C Urea Breath Test Kits represent the leading segment of the Urea Breath Test Market, accounting for 72% share in 2025 with revenue of USD 291.6 million. These kits support accurate, non-invasive detection of Helicobacter pylori infections by providing standardized carbon-13 labeled urea, optimized testing components, and reliable breath sample collection systems. Increasing preference for radiation-free diagnostics, repeat testing after eradication therapy, and wider adoption in pediatric and sensitive patient groups are strengthening demand for ¹³C-based breath testing solutions.

Fastest Growing Segment: Breath Analyzers and Detection Systems

Market Share (2025): 28% | Revenue: USD 113.4 Million | CAGR (2026–2032): 5.10%

Breath analyzers and detection systems represent the leading diagnostic component of the Urea Breath Test (UBT) Market, accounting for 28% share in 2025 with revenue of USD 113.4 million. These systems detect Helicobacter pylori infection by measuring the change in ¹³CO2 and ¹²CO2 isotope ratios in exhaled breath after ingestion of labeled urea, enabling non-invasive diagnosis and post-treatment eradication assessment.

The segment growth is supported by increasing preference for accurate, patient-friendly diagnostic methods and adoption of advanced infrared spectrometry, isotope ratio mass spectrometry, and automated real-time breath analysis platforms across hospitals and diagnostic laboratories. With a 5.10% CAGR during 2026–2032, breath analyzer technologies are expected to remain central to UBT-based H. pylori testing as healthcare providers shift toward faster and minimally invasive detection approaches.

 

By Test Type

Leading Segment: Laboratory-Based Urea Breath Testing

Laboratory-based urea breath testing represents the dominant segment of the Urea Breath Test Market, accounting for 65% share in 2025 with revenue of USD 263.3 million. These laboratory systems provide high-precision detection of active Helicobacter pylori infection by analyzing isotope-labeled carbon dioxide levels in patient breath samples. Demand is supported by their widespread use in hospitals, diagnostic laboratories, and clinical centers for accurate diagnosis and post-treatment verification.

Laboratories compare baseline and post-dose breath samples to measure ¹³CO2/¹²CO2 ratios or ¹4CO2 activity, using advanced analytical platforms such as isotope ratio mass spectrometry and infrared-based detection systems. The segment is projected to grow at a CAGR of 5.25% during 2026–2032, supported by increasing non-invasive diagnostic adoption, rising H. pylori screening, and continued preference for reliable test-of-cure procedures after eradication therapy.

Fastest Growing Segment: Point-of-Care Testing (POCT)

Point-of-care testing (POCT) is gaining importance in the Urea Breath Test (UBT) Market by enabling rapid Helicobacter pylori detection at clinics, physician offices, and bedside settings without dependence on centralized laboratories. In 2025, POCT accounted for 35% of the Urea Breath Test Market, generating USD 141.8 million in revenue, with demand expected to expand at a 7.05% CAGR from 2026 to 2032 as healthcare providers prioritize faster diagnosis, immediate treatment decisions, and decentralized testing access.

 

By Application / End User

Leading Segment: Hospitals

Hospitals represent the leading end-user segment in the Urea Breath Test (UBT) Market, accounting for 55% market share in 2025 with revenue of USD 222.8 million. The segment is projected to grow at a CAGR of 5.55% during 2026–2032, supported by increasing Helicobacter pylori diagnosis volumes, availability of specialized diagnostic laboratories, and growing adoption of non-invasive testing methods for treatment confirmation. Hospitals provide controlled clinical environments with trained personnel, laboratory infrastructure, and specialist supervision required for accurate UBT administration and analysis.

Hospital-based UBT services involve patient preparation, isotope-labeled urea administration, breath sample collection, and laboratory interpretation using technologies such as isotope-ratio mass spectrometry and infrared spectroscopy. Hospitals also use UBT for post-treatment verification after H. pylori eradication therapy, supporting recurring demand for diagnostic testing across gastroenterology departments.

Fastest Growing Segment: Physical Examination & Wellness Centers

Physical Examination and Wellness Centers represent an emerging channel within the Urea Breath Test (UBT) Market, supporting early Helicobacter pylori (H. pylori) detection through preventive health screenings, patient assessment, and non-invasive diagnostic services. These centers help expand UBT adoption by identifying individuals with recurring gastrointestinal symptoms and directing them toward accurate testing before advanced diagnostic procedures are considered. Their growing role in preventive healthcare models is contributing to steady demand for UBT solutions, with this segment generating USD 20.3 million in revenue in 2025 and expected to grow at a CAGR of 7.20% during 2026–2032.

 

By Geography

Leading and Fastest Growing Segment Segment: Asia-Pacific

Asia-Pacific Urea Breath Test Market accounted for 34% of global revenue in 2025, generating USD 137.7 million, and is projected to expand at a CAGR of 7.15% during 2026–2032. Regional demand is supported by the widespread use of Urea Breath Testing for non-invasive Helicobacter pylori (H. pylori) detection and confirmation of eradication after treatment. Rising H. pylori screening volumes, increasing follow-up testing after eradication therapy, and stronger gastric cancer prevention programs are expanding UBT utilization across gastroenterology clinics, hospitals, and diagnostic laboratories.

 

Real-Time Analytics and Portable Systems Reshape Breath Testing

Automated Real-Time Breath Analysis Systems Improving Diagnostic Speed

The Urea Breath Test Market is moving toward automated analyzers that can measure isotope changes continuously rather than relying on manual sample collection and laboratory processing. Advanced platforms such as BreathID® Hp systems use continuous real-time ¹³C measurement technology, enabling clinicians to complete H. pylori detection within approximately 10–15 minutes while generating immediate results at the point of testing. The system received FDA clearance for clinical use, supporting adoption across hospitals and gastroenterology clinics.

These automated platforms are reducing operator dependency, improving workflow efficiency, and supporting higher testing volumes in healthcare facilities where rapid diagnosis and treatment decisions are increasingly important.

 

Shift Toward Non-Radioactive ¹³C Urea Breath Testing

A major technological shift in the market is the increasing preference for ¹³C-labelled urea tests over ¹4C-based methods. ¹³C UBT uses a stable carbon isotope, eliminating radioactive exposure concerns and making it suitable for repeated testing, pediatric populations, and post-eradication monitoring.

The test detects labeled carbon dioxide produced when H. pylori urease breaks down urea in the stomach. Detection technologies including infrared spectroscopy and isotope ratio mass spectrometry (IRMS) allow accurate measurement of carbon isotope changes in exhaled breath.

This transition is strengthening demand for advanced ¹³C kits and compatible analyzer systems across hospitals and diagnostic laboratories.

 

Development of Compact and Point-of-Care Breath Analyzers

Manufacturers are focusing on smaller, easier-to-use breath analyzers that allow testing outside centralized laboratories. Portable infrared-based analyzers are enabling gastroenterology clinics, outpatient facilities, and smaller diagnostic centers to perform UBT without depending on external reference laboratories.

The expansion of point-of-care diagnostics is particularly relevant in regions with high H. pylori prevalence, where improving access to rapid testing can increase diagnosis rates. The ability to provide results within minutes supports faster treatment initiation and improves patient convenience.

 

Digital Integration and Automated Reporting Platforms

New-generation UBT systems are increasingly incorporating digital connectivity features such as automated patient data entry, electronic reporting, and software-based interpretation. These capabilities help reduce transcription errors and improve integration with hospital information systems.

The movement toward connected diagnostic devices aligns with broader healthcare digitization trends, where laboratories and hospitals are seeking solutions that combine testing accuracy with efficient data management.

 

At-Home and Remote Breath Testing Models

Research and pilot programs are exploring decentralized UBT models where patients collect breath samples at home and submit them for analysis. These approaches aim to reduce hospital visits, improve accessibility for patients in remote areas, and support population-level screening programs.

Home-based diagnostic models are becoming increasingly relevant as healthcare systems look for ways to manage growing gastrointestinal disease screening demand while reducing pressure on specialist clinics.

 

Miniaturized Sensors and Next-Generation Breath Detection Technologies

Research efforts are focused on developing miniature sensor technologies capable of detecting breath biomarkers using smaller, lower-cost devices. These innovations could enable future smartphone-connected or handheld breath diagnostic platforms.

Although most applications remain under development, miniaturized sensing technologies represent a potential pathway toward affordable, decentralized H. pylori testing, particularly in emerging healthcare markets.

 

Automated Platforms and Isotope Kits Define Supplier Competition

Meridian Bioscience, Inc. (BreathID® Platform)

Meridian Bioscience is among the prominent players in the Urea Breath Test Market, driven by its automated BreathID® H. pylori testing platforms designed for rapid, non-invasive detection of Helicobacter pylori. The company’s systems focus on improving diagnostic workflow through automated breath collection, real-time isotope measurement, and digital result reporting, reducing dependence on manual laboratory processing.

The BreathID technology uses continuous real-time ¹³C measurement, enabling clinicians to complete testing within approximately 10–15 minutes, compared with traditional laboratory-based approaches that may require additional processing time. The platform has received regulatory clearances, including FDA clearance for BreathID Hp in 2013, supporting adoption across hospitals, gastroenterology clinics, and diagnostic facilities.

Meridian’s commercial strength comes from addressing key market requirements: faster turnaround time, reduced operator variability, and higher testing efficiency. As healthcare providers increasingly move toward point-of-care diagnostics and decentralized testing, automated breath analyzers are becoming strategically important within the UBT ecosystem.

SSI Diagnostica Group (PyloPlus® ¹³C Urea Breath Test System)

SSI Diagnostica Group is a significant participant in the Urea Breath Test Market through its PyloPlus® ¹³C-urea breath test solutions, which provide non-radioactive diagnostic testing for active H. pylori infection. The company focuses on supplying complete testing solutions combining ¹³C urea substrates, breath collection systems, and analyzer compatibility for hospitals and diagnostic laboratories.

The company’s product positioning aligns with the growing preference for stable isotope-based testing, as ¹³C UBT avoids radioactive exposure associated with ¹4C-based methods and supports repeated testing, including eradication confirmation after treatment. ¹³C breath testing relies on isotope detection methods such as infrared spectroscopy or isotope ratio mass spectrometry to measure labeled carbon dioxide after urea metabolism by H. pylori.

SSI Diagnostica’s role is strengthened by demand from laboratories seeking standardized, clinically validated testing workflows rather than standalone diagnostic components.

Regional Suppliers Extend Breath Testing Reach

• Kibion AB (Mayoly Spindler Group) – Provides ¹³C urea breath testing solutions and analyzer systems, supporting gastrointestinal diagnostics across European and international healthcare markets.

• Exalenz Bioscience – Develops BreathID-based automated diagnostic platforms focused on rapid real-time H. pylori detection; its BreathID Hp system received FDA clearance for clinical use.

• Beijing Richen-Force Science & Technology Co., Ltd. – Supplies ¹³C urea breath test kits and infrared analyzers, strengthening adoption of breath diagnostics in Asia-Pacific markets.

• Quest Diagnostics – Supports UBT adoption through large-scale diagnostic testing services and laboratory processing capabilities in the United States.

• Labcorp – Provides reference laboratory infrastructure for gastrointestinal diagnostic testing, including outsourced breath test analysis.

• Avanos Medical, Inc. – Participates in gastrointestinal healthcare solutions, supporting broader digestive disease management applications.

 

Analyst View: Faster Testing Broadens the Diagnostic Pathway

The Urea Breath Test Market is shifting from conventional laboratory-based diagnosis toward automated, non-invasive, and decentralized H. pylori detection solutions. Increasing preference for ¹³C urea breath testing, rising demand for post-eradication confirmation, and adoption of automated breath analyzers are reshaping diagnostic workflows across hospitals and laboratories. The next phase of market growth is expected to be driven by point-of-care platforms, portable analyzers, and digital testing solutions that improve accessibility and turnaround time.

 

Urea Breath Test Market Report Coverage at a Glance

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 405 Million
Revenue Forecast in 2032	USD 606 Million
Overall Growth Rate	CAGR of 5.85% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026–2032)
Segmentation	By Product Type, By Test Type, By Application / End User, By Geography
By Product Type	¹³C Urea Breath Test Kits, Breath Analyzers and Detection Systems
By Test Type	Laboratory-Based Urea Breath Testing, Point-of-Care Testing (POCT)
By Application / End User	Hospitals, Diagnostic Centers & Standalone Laboratories, Specialized Gastroenterology Clinics, Physical Examination and Wellness Centers
By Geography	North America, Asia-Pacific, Europe, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, France, Netherlands, China, India, South Korea, Japan, Brazil, Mexico, UAE, Saudi Arabia, South Africa
Market Drivers	Rising global H. pylori prevalence, increasing demand for accurate treatment confirmation, healthcare cost optimization, and advances in portable breath analytics
Customization Option	Available upon request